U.S. health regulators are considering a policy change that could expand access to certain peptide injections, putting the safety and regulation of popular wellness treatments back in the spotlight.

The Food and Drug Administration (FDA) has submitted a proposed policy on compounding certain peptides for White House review, according to Reuters. The move could allow compounding pharmacies to prepare specified substances under an interim access framework, although the full policy details have not yet been disclosed.

Peptides are short chains of amino acids that have attracted growing attention in wellness and fitness communities. Some are promoted online for muscle recovery, anti-aging and other benefits, but many of the products under consideration have not been approved by the FDA as safe and effective for these uses.

FDA advisers previously recommended easing restrictions on several peptides, including BPC-157. However, concerns remain about limited clinical evidence, product quality and potential risks.

The proposed change could affect compounding pharmacies, telehealth providers and consumers seeking alternative wellness treatments. Any eventual policy will depend on the administration’s review and the conditions regulators establish.

For consumers, wider access would not necessarily mean a treatment is proven safe or effective. Healthcare professionals recommend discussing unapproved products with a qualified clinician and checking current FDA guidance before considering their use.